Skip to the main content.

Cell and Gene Therapy Series. Part 3 - Clusters, Megadeals, "Cellicon Valley" and the "Golden Triangle

Dr. Dave Seaward : 28 February 2022

Cell and Gene Therapy Series. Part 3 - Clusters, Megadeals,

In this third instalment to our cell and gene blog series, author Dave Seaward explains where most ATMP technology is being delivered as well as providing insight into why.

Click here to gain an understanding of why investors believe significant returns will be made from these technologies.
Understanding aseptic powder filling: Key principles & techniques

Understanding aseptic powder filling: Key principles & techniques

David Johnson: 25 September 2024

Aseptic powder filling is a critical step in pharmaceutical production, particularly for medications that require sterile administration such as...

Read More
Shaping the future of ATMPs: tailored automation and advanced technologies for the next decade

Shaping the future of ATMPs: tailored automation and advanced technologies for the next decade

Dr. Dave Seaward: 30 September 2024

If history is to repeat itself, the next 10 years will see significant activity regarding the automation of advanced therapy medicinal products (ATMPs

Read More
The Basics of Cell Culture: Key Steps in Manufacturing Cell Therapies

The Basics of Cell Culture: Key Steps in Manufacturing Cell Therapies

David Johnson: 10 July 2024

Introduction Cell therapies represent a promising frontier in medicine, offering potential treatments and cures for a wide range of diseases....

Read More